These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37904221)

  • 21. Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
    Liang S; Wei Z; Fang H; Guan T
    Int J Rheum Dis; 2023 Sep; 26(9):1686-1696. PubMed ID: 37496262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials.
    Wang Y; Han M; Pedigo CE; Xie ZM; Wang WJ; Liu JP
    Chin J Integr Med; 2021 Oct; 27(10):778-787. PubMed ID: 34319503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
    Oon S; Huq M; Godfrey T; Nikpour M
    Semin Arthritis Rheum; 2018 Oct; 48(2):221-239. PubMed ID: 29426575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
    Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of belimumab therapy in systemic lupus erythematosus: A systematic review and meta-analysis.
    Chiang HY; Guo ZA; Wu TW; Peng TR
    Lupus; 2022 May; 31(6):666-673. PubMed ID: 35321609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.
    Morand E; Smolen JS; Petri M; Tanaka Y; Silk M; Dickson C; Meszaros G; de la Torre I; Issa M; Zhang H; Dörner T
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37604638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.
    Wang B; Pan S; Yao Y; Zeng L; Zhang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1139-1149. PubMed ID: 35876397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis.
    Tselios K; Wakani L; Gladman DD; Su J; Urowitz MB
    Rheumatology (Oxford); 2021 Jan; 60(1):73-80. PubMed ID: 33140092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total Glucosides of
    Chen Y; Wang L; Cao Y; Li N
    Front Pharmacol; 2022; 13():834947. PubMed ID: 35173622
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
    Kalunian KC; Urowitz MB; Isenberg D; Merrill JT; Petri M; Furie RA; Morgan-Cox MA; Taha R; Watts S; Silk M; Linnik MD
    Rheumatology (Oxford); 2018 Jan; 57(1):125-133. PubMed ID: 29045736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis].
    Liu S; Guo YL; Yang JY; Wang W; Xu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1014-1021. PubMed ID: 30562774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.
    Li J; Wei MM; Song Q; Guo XH; Shao L; Liu Y
    Exp Ther Med; 2019 Aug; 18(2):1500-1506. PubMed ID: 31316634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.